Salius Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 31-07-2024
- Paid Up Capital ₹ 0.99 Cr
as on 31-07-2024
- Company Age 13 Year, 7 Days
- Last Filing with ROC 31 Mar 2023
- Revenue 57.53%
(FY 2023)
- Profit 98.91%
(FY 2023)
- Ebitda 386.75%
(FY 2023)
- Net Worth 10.14%
(FY 2023)
- Total Assets 10.38%
(FY 2023)
About Salius Pharma
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 0.99 Cr, as per Ministry of Corporate Affairs (MCA) records.
Abani Patra, Rajdev Gulia, and Arati Patra serve as directors at the Company.
- CIN/LLPIN
U24233MH2011PTC223680
- Company No.
223680
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Nov 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Navi Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Salius Pharma Private Limited offer?
Salius Pharma Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Antipyretic Medication, Common Disease Medicines, Pharmaceutical Medicine, Industrial Chemicals & Supplies, Sewage Treatment Chemical, Ayurvedic Powder and Medicinal Herbs, Herbal Powder, Animal Medicines & Health Care, Anthelmintics.
Who are the key members and board of directors at Salius Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajdev Gulia  | Director | 18-Mar-2013 | Current |
Abani Patra  | Director | 05-Nov-2011 | Current |
| Arati Patra | Director | 17-Jan-2017 | Current |
Financial Performance and Corporate Structure Insights of Salius Pharma.
Salius Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 57.53% increase. The company also saw a substantial improvement in profitability, with a 98.91% increase in profit. The company's net worth Soared by an impressive increase of 10.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Salius Pharma?
In 2023, Salius Pharma had a promoter holding of 84.50% and a public holding of 15.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Salius Pharma?
Salius Pharma has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Salius Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Salius Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
